Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin alfa every 3 weeks with or without parenteral iron in chemotherapy-induced anemia
2004-001417-33Phase 3Completed
- Sponsor
- Amgen
- Start
- Aug 2004
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of darbepoetin alfa, iron sucrose and sodium ferric gluconate in chemotherapy-induced anaemia (CIA) (2 arms), sponsored by Amgen. Primary endpoint: Hematopoietic response during treatment period. Started Aug 2004; status: completed.
02
Drugs
darbepoetin alfairon sucrosesodium ferric gluconate
03
Conditions
chemotherapy-induced anaemia (CIA)
Beyond the preview
Go deeper on 2004-001417-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001417-33.